42,343 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Acquired by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 42,343 shares of the medical equipment provider’s stock, valued at approximately $4,571,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. BLB&B Advisors LLC raised its holdings in Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after buying an additional 100 shares during the period. FWG Holdings LLC boosted its stake in Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after purchasing an additional 101 shares during the period. Financial Advocates Investment Management grew its position in Zimmer Biomet by 3.5% during the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after purchasing an additional 103 shares in the last quarter. M&R Capital Management Inc. lifted its holdings in shares of Zimmer Biomet by 14.1% in the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 105 shares in the last quarter. Finally, Mill Creek Capital Advisors LLC boosted its position in shares of Zimmer Biomet by 5.1% in the second quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after buying an additional 106 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on ZBH. Wolfe Research began coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They set a “peer perform” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Wells Fargo & Company lifted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Canaccord Genuity Group cut their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 10th. Finally, JPMorgan Chase & Co. reduced their price target on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Stock Performance

ZBH opened at $110.95 on Wednesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The firm has a market capitalization of $22.09 billion, a P/E ratio of 21.09, a price-to-earnings-growth ratio of 2.08 and a beta of 1.02. The stock’s 50 day moving average price is $106.56 and its two-hundred day moving average price is $109.86. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.65 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.